论文部分内容阅读
目的:探究新生儿B组链球菌(GBS)感染导致的化脓性脑膜炎的临床药物干预的有效途径。方法:该院产后新生儿经B组链球菌免疫学抗原检查阳性并经脑脊液检查确诊的化脓性脑膜炎患者60例,经伦理审查通过,并与患者家属签署知情同意书,将患儿等量随机分为联合治疗组30例(头孢曲松钠联合氨苄西林治疗)和对照组30例(单纯氨苄西林治疗)。两组均辅助地塞米松及丙种免疫球蛋白基础治疗,比较两组患者临床症状的缓解及其不良事件的发生率。结果:脑膜炎患儿早期药物预防联合治疗组的临床症状缓解的平均水平明显优于对照组,差异具有统计学意义(P<0.05);在随访期合并并发症发生率联合治疗组(0)低于对照组(13.3%),差异具有统计学意义(P<0.05)。结论:联合治疗组治疗新生儿B组链球菌感染所致化脓性脑膜炎的效果较好,为临床治疗提供一定程度的支持。
Objective: To explore an effective way of clinical drug intervention for purulent meningitis caused by neonatal group B streptococcus (GBS) infection. Methods: Sixty cases of purulent meningitis confirmed by group B streptococcal immunological antigen test and confirmed by cerebrospinal fluid after birth in this hospital were ethically reviewed and signed informed consent form with their families, Thirty patients were randomly divided into combined treatment group (ceftriaxone sodium plus ampicillin treatment) and control group (n = 30) (ampicillin alone treatment). Both groups assisted with basic treatment of dexamethasone and immunoglobulin C. The clinical symptoms and the incidence of adverse events in both groups were compared. Results: The average clinical symptom relief rate of patients with meningitis was significantly better than that of the control group (P <0.05). In the follow-up period, the incidence rate of combined complication in the combination therapy group (0) Lower than the control group (13.3%), the difference was statistically significant (P <0.05). Conclusion: The combined treatment group is effective in treating purulent meningitis caused by streptococcal infection in group B, providing some support for clinical treatment.